{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:13:53Z","timestamp":1790662433760,"version":"4.1.0"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) has become one of the most common diseases and severe problems worldwide because of the global increase in obesity, dyslipidemia, hypertension, and type 2 diabetes mellitus. NAFLD includes a wide spectrum of liver diseases, the histological forms of which range from non-alcoholic fatty liver (NAFL), which is generally nonprogressive, to non-alcoholic steatohepatitis (NASH), which can progress to chronic hepatitis, liver cirrhosis (LC), and sometimes hepatocellular carcinoma (HCC). Unlike NAFL, as the progressive form of NAFLD, NASH is characterized by the presence of inflammation with or without fibrosis in addition to hepatic steatosis. Although it is widely known and proved that persistent hepatic injury and chronic inflammation in the liver activate quiescent hepatic stellate cells (HSCs) and lead to hepatic fibrosis, the three-step process of \u201cinflammation-fibrosis-carcinoma\u201d in NAFLD has not been investigated and clarified clearly. In this process, the initiation of inflammation in the liver and the function of various liver inflammatory cells have been discussed regularly, while the activated HSCs, which constitute the principal cells responsible for fibrosis and their cross-talk with inflammation, seem not to be investigated specifically and frequently. Also, accumulated evidence suggests that HSCs can not only be activated by inflammation but also participate in the regulation of liver inflammation. Therefore, it is necessary to investigate the unique roles of HSCs in NAFLD from the perspective of inflammation and fibrosis. Here, we review the pivotal effects and mechanisms of HSCs and highlight the potential value of HSC-targeted treatment methods in NAFLD.<\/jats:p>","DOI":"10.3389\/fphar.2022.958428","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T03:35:01Z","timestamp":1665632101000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":49,"title":["Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Man","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changquan","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/hep.30094","article-title":"Healthcare cost and utilization in nonalcoholic fatty liver disease: Real-world data from a large U.S. Claims database","volume":"68","author":"Allen","year":"2018","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2019.14231","article-title":"Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity","volume":"322","author":"Aminian","year":"2019","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"105922","DOI":"10.1016\/j.cct.2019.105922","article-title":"Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA phase 3 study design","volume":"89","author":"Anstee","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"B4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"key":"B5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/MOL.0b013e32835cc949","article-title":"Peroxisome proliferator-activated receptor \u03b4: a multifaceted metabolic player","volume":"24","author":"Bojic","year":"2013","journal-title":"Curr. Opin. Lipidol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/MOG.0000000000000349","article-title":"Intestinal microbiota and nonalcoholic steatohepatitis","volume":"33","author":"Brandl","year":"2017","journal-title":"Curr. Opin. Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.3390\/ijms23095146","article-title":"Lipotoxicity as the leading cause of non-alcoholic steatohepatitis","volume":"23","author":"Brankovi\u0107","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"G211","DOI":"10.1152\/ajpgi.00040.2019","article-title":"CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease","volume":"318","author":"Breuer","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1002\/bit.27379","article-title":"Differential fibrotic phenotypes of hepatic stellate cells within 3D liver organoids","volume":"117","author":"Brovold","year":"2020","journal-title":"Biotechnol. Bioeng."},{"key":"B10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1172\/JCI22422","article-title":"Molecular mediators of hepatic steatosis and liver injury","volume":"114","author":"Browning","year":"2004","journal-title":"J. Clin. Invest."},{"key":"B11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/01.lab.0000069036.63405.5c","article-title":"Apoptotic body engulfment by a human stellate cell line is profibrogenic","volume":"83","author":"Canbay","year":"2003","journal-title":"Lab. Invest."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2337\/db06-1491","article-title":"Metabolic endotoxemia initiates obesity and insulin resistance","volume":"56","author":"Cani","year":"2007","journal-title":"Diabetes (New York, N.Y.)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s41467-019-09455-9","article-title":"A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease","volume":"10","author":"Caussy","year":"2019","journal-title":"Nat. Commun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.1204265","article-title":"Human fatty liver disease: Old questions and new insights","volume":"332","author":"Cohen","year":"2011","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/s0168-8278(99)80192-5","article-title":"Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells","volume":"30","author":"Desmouli\u00e8re","year":"1999","journal-title":"J. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: Clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.3748\/wjg.v24.i27.2974","article-title":"Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From \u201ctwo hit theory\u201d to \u201cmultiple hit model\u201d","volume":"24","author":"Fang","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4103\/2277-9175.176368","article-title":"Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver","volume":"5","author":"Foroughi","year":"2016","journal-title":"Adv. Biomed. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"7449","DOI":"10.26355\/eurrev_202112_27442","article-title":"A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients","volume":"25","author":"Fouda","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1074\/jbc.275.4.2247","article-title":"Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury","volume":"275","author":"Friedman","year":"2000","journal-title":"J. Biol. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.cct.2016.02.012","article-title":"Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR phase 2b study design","volume":"47","author":"Friedman","year":"2016","journal-title":"Contemp. Clin. Trials"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-016-0005-6","article-title":"Roles of hepatic stellate cells in liver inflammation: a new perspective","volume":"36","author":"Fujita","year":"2016","journal-title":"Inflamm. Regen."},{"key":"B28","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s12072-013-9468-6","article-title":"Immune and inflammatory pathways in NASH","volume":"7","author":"Ganz","year":"2013","journal-title":"Hepatol. Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jhep.2019.12.010","article-title":"Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension","volume":"72","author":"Garcia-Tsao","year":"2020","journal-title":"J. Hepatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/liv.12611","article-title":"Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease","volume":"35","author":"Goh","year":"2015","journal-title":"Liver Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jconrel.2005.12.010","article-title":"Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology","volume":"111","author":"Gonzalo","year":"2006","journal-title":"J. Control. Release"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","article-title":"A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis","volume":"72","author":"Harrison","year":"","journal-title":"J. Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"","journal-title":"J. Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"B37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s0168-8278(99)80010-5","article-title":"The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo","volume":"30","author":"Hellerbrand","year":"1999","journal-title":"J. Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"B39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/jama.2017.20813","article-title":"Lifestyle intervention and medical management with vs without roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 Years in the diabetes surgery study","volume":"319","author":"Ikramuddin","year":"2018","journal-title":"JAMA"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1113\/JP281061","article-title":"Hepatic stellate cells in physiology and pathology","volume":"600","author":"Kamm","year":"2022","journal-title":"J. Physiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano","year":"2013","journal-title":"J. Gastroenterol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"9448","DOI":"10.1073\/pnas.1201840109","article-title":"Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis","volume":"109","author":"Kisseleva","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0158156","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic effects of the dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis","volume":"11","author":"Lefebvre","year":"2016","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1600-065X.2007.00579.x","article-title":"The grateful dead: damage-associated molecular pattern molecules and reduction\/oxidation regulate immunity","volume":"220","author":"Lotze","year":"2007","journal-title":"Immunol. Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1053\/j.gastro.2014.07.018","article-title":"Cell death and cell death responses in liver disease: Mechanisms and clinical relevance","volume":"147","author":"Luedde","year":"2014","journal-title":"Gastroenterology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1001\/jamasurg.2016.2317","article-title":"Bariatric surgery and long-term durability of weight loss","volume":"151","author":"Maciejewski","year":"2016","journal-title":"JAMA Surg."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5170402","DOI":"10.1155\/2016\/5170402","article-title":"Pathogenesis of nonalcoholic steatohepatitis: Interactions between liver parenchymal and nonparenchymal cells","volume":"2016","author":"Magee","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1038\/s41598-019-39112-6","article-title":"Transcriptional regulation of hepatic stellate cell activation in NASH","volume":"9","author":"Marcher","year":"2019","journal-title":"Sci. Rep."},{"key":"B50","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrendo.2017.56","article-title":"Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance","volume":"13","author":"Meex","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/JIR.S35227","article-title":"Alleviation of insulin resistance and liver damage by oral administration of imm124-E is mediated by increased tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I\/II clinical trial in NASH","volume":"5","author":"Mizrahi","year":"2012","journal-title":"J. Inflamm. Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.7150\/thno.57689","article-title":"Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS","volume":"11","author":"Oh","year":"2021","journal-title":"Theranostics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"8591","DOI":"10.3390\/ijms15058591","article-title":"Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation","volume":"15","author":"Peverill","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/s0168-8278(02)00414-2","article-title":"Influence of leptin in the development of hepatic fibrosis produced in mice by Schistosoma mansoni infection and by chronic carbon tetrachloride administration","volume":"38","author":"Potter","year":"2003","journal-title":"J. Hepatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e0126769","DOI":"10.1371\/journal.pone.0126769","article-title":"The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis","volume":"10","author":"Potts","year":"2015","journal-title":"PLoS one"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/hep4.1434","article-title":"Liver-targeted angiotensin converting enzyme 2 therapy inhibits chronic biliary fibrosis in multiple drug-resistant gene 2-knockout mice","volume":"3","author":"Rajapaksha","year":"2019","journal-title":"Hepatol. Commun."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J. Hepatol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","article-title":"Mechanisms for insulin resistance: common threads and missing links","volume":"148","author":"Samuel","year":"2012","journal-title":"Cell"},{"key":"B64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.peptides.2013.05.010","article-title":"Oral Angiotensin-(1-7) prevented obesity and hepatic inflammation by inhibition of resistin\/TLR4\/MAPK\/NF-\u03baB in rats fed with high-fat diet","volume":"46","author":"Santos","year":"2013","journal-title":"Peptides"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: Data from the Simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cld.2015.10.001","article-title":"Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world","volume":"20","author":"Sayiner","year":"2016","journal-title":"Clin. Liver Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH.","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrgastro.2017.42","article-title":"NASH: Novel therapeutic strategies targeting ASK1 in NASH","volume":"14","author":"Schuster","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-\u03b2 signaling and hepatic fibrosis","volume":"13","author":"Seki","year":"2007","journal-title":"Nat. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/hep.27332","article-title":"Hepatic inflammation and fibrosis: functional links and key pathways","volume":"61","author":"Seki","year":"2015","journal-title":"Hepatology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.1074\/jbc.M410078200","article-title":"Adipogenic transcriptional regulation of hepatic stellate cells","volume":"280","author":"She","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: A review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"B74","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3904\/kjim.2017.317","article-title":"Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension","volume":"33","author":"Shim","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.3748\/wjg.v23.i19.3396","article-title":"Renin angiotensin system in liver diseases: Friend or foe?","volume":"23","author":"Sim\u00f5es","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1586\/egh.11.92","article-title":"Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques","volume":"6","author":"Tacke","year":"2014","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1111\/liv.12523","article-title":"Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?","volume":"34","author":"Tariq","year":"2014","journal-title":"Liver Int."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/oby.2007.114","article-title":"ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats","volume":"16","author":"Toblli","year":"2008","journal-title":"Obes. (Silver Spring)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"230","DOI":"10.31662\/jmaj.2021-0199","article-title":"Positive pattern recognition system using alanine aminotransferase, type IV collagen 7s, and E value (liver stiffness) for the diagnosis of nonalcoholic steatohepatitis based on natural history.","volume":"5","author":"Tsujisaki","year":"2022","journal-title":"Based Nat. Hist."},{"key":"B83","doi-asserted-by":"publisher","first-page":"33453","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci. Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"S348","DOI":"10.1016\/s0168-8278(11)60875-1","article-title":"progression of NAFLD in humans is associated with the activation of the renin-angiotensin system","volume":"54","author":"Vergniol","year":"2011","journal-title":"J. Hepatology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejphar.2007.06.039","article-title":"Effect of fetuin, a TGFbeta antagonist and pentoxifylline, a cytokine antagonist on hepatic stellate cell function and fibrotic parameters in fibrosis","volume":"572","author":"Verma-Gandhu","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/hep.24148","article-title":"Nuclear receptors in liver disease","volume":"53","author":"Wagner","year":"2011","journal-title":"Hepatology"},{"key":"B88","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.molimm.2017.04.003","article-title":"TWEAK\/Fn14 promotes pro-inflammatory cytokine secretion in hepatic stellate cells via NF-\u03baB\/STAT3 pathways","volume":"87","author":"Wang","year":"2017","journal-title":"Mol. Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.2353\/ajpath.2009.080697","article-title":"Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats","volume":"174","author":"Wei","year":"2009","journal-title":"Am. J. Pathol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrgastro.2013.149","article-title":"From NAFLD to NASH to cirrhosis-new insights into disease mechanisms","volume":"10","author":"Wree","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3389\/fphar.2020.00432","article-title":"Liraglutide attenuates non-alcoholic fatty liver disease in mice by regulating the local renin-angiotensin system","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1756-0500-2-70","article-title":"Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat","volume":"2","author":"Yoshiji","year":"2009","journal-title":"BMC Res. Notes"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"B94","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41467-019-14138-6","article-title":"SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat. Commun."},{"key":"B95","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/biomedicines9040365","article-title":"Hepatic stellate cell activation and inactivation in NASH-fibrosis\u2014roles as putative treatment targets?","volume":"9","author":"Zisser","year":"2021","journal-title":"Biomedicines"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.958428\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T03:35:06Z","timestamp":1665632106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.958428\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":95,"alternative-id":["10.3389\/fphar.2022.958428"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.958428","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"article-number":"958428"}}